CSTL (Castle Biosciences) Tariff Resilience Score: 7/10 (As of Jun. 30, 2026)


CSTL Castle Biosciences Inc CSTL
73 GF Score
Price $24.30
GF Value $29.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Tariff Resilience Score?

Castle Biosciences CSTL +0.45% 73 Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 95.81% on this metric.

Castle Biosciences has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Castle Biosciences has Moderate resilience with some exposure to international supply chains. Primarily domestic sales reduce risk, and the company has some ability to adjust pricing. Historical tariff impacts are minimal.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Castle Biosciences might have Highly Resilient.

Castle Biosciences  (NAS:CSTL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Castle Biosciences Tariff Resilience Score Related Terms

CSTL vs FLGT, MYGN, OPK: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Castle Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Castle Biosciences Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's Tariff Resilience Score falls into.


CSTL
73GF Score
Castle Biosciences Inc CSTL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Castle Biosciences (CSTL) has a Tariff Resilience Score of 7 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Castle Biosciences ranks #9 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is Castle Biosciences' Tariff Resilience Score too high?
Castle Biosciences' current Tariff Resilience Score is 7. Based on the distribution chart, Castle Biosciences ranks #9 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Tariff Resilience Score compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #9 out of 215 companies for Tariff Resilience Score. This places Castle Biosciences in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Castle Biosciences's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.30 — trading 16.7% below its estimated fair value. The current Tariff Resilience Score is 7. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.30 is trading 16.7% below its estimated GF Value™ of $29.16. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • Tariff Resilience Score: 7
  • GF Value™: $29.16 vs. price of $24.30 (16.7% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
73GF Score

Get the complete analysis for CSTL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.30
Price
$29.16
GF Value